Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Regeneron-1787 for Cutaneous Squamous Cell Carcinoma - Clinical Trial

What is the Purpose of this Study?

We are doing the study to understand how your body reacts to the study drug, Cemiplimab.
What is the Condition Being Studied?
Recurrent Cutaneous Squamous Cell Carcinoma (a type of skin cancer that keeps returning)

Who Can Participate in the Study?

Adults with Squamous Cell Carcinoma that keeps coming back.
-The lesion must be about a half inch to one inch across

Age Group

What is Involved?

If you choose to be in this study, you will:
-Get injected with the study drug (Cemiplimab) for 12 weeks
-Have a Blood draw
-Get a small biopsy of the skin
-Have an x-ray of your chest
-Give a urine sample

Study Details

Full Title
A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients with Recurrent Cutaneous Squamous Cell Carcinoma (CSCC)
Principal Investigator
Protocol Number
IRB: PRO00101552
NCT: NCT03889912
Phase I
Contact the Duke Recruitment Innovation Center